The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma

Molecular Biology Reports

Volumn 40, Issue 12, 2013, Pages 6525-6531

  Wang, Cong Jun ^a   Tang, Lin ^a   Shen, Dong Wei ^a   Wang, Chao ^a   Yuan, Qiong Ying ^a   Gao, Wei ^a   Wang, Yong Kun ^a   Xu, Rong Hua ^b   Zhang, Hui ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; DFNA5; Hepatocellular carcinoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5; ONCOPROTEIN; PROTEIN DFNA5; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DFNA5 GENE; FLOW CYTOMETRY; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR DYNAMICS; ONCOGENE; PROTEIN DENATURATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; RECEPTORS, ESTROGEN; TRANSFECTION;

EID: 84890425483     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2581-8     Document Type: Article

References (35)

1. Abrams P, Marsh JW (2010) Current approach to hepatocellular carcinoma. Surg Clin North Am 90(4):803-816. doi: S0039-6109(10)00045-9 10.1016/j.suc.2010.04.010
2. Tan YJ (2011) Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 17(44):4853-4857. doi: 10.3748/wjg.v17.i44.4853
3. Cabibbo G, Craxi A (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14(4):352-355
4. Toyota M (2005) Issa J Epigenetic changes in solid and hematopoietic tumors. Seminars in oncology, In, p 521
5. Zhang YJ, Wu HC, Yazici H, Yu MW, Lee PH, Santella RM (2012) Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B1 exposure. World J hepatol 4(5):169
6. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A (2007) Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Bri J cancer 97(9):1260-1265
7. Saelee P, Petmitr S, Wongkham S, Chariyalertsak S, Homcha-cm P (2010) Detection of DNA methylation of p16INK4a in hepatocellular carcinoma by methylation specific-polymerase chain reaction. Thai Cancer J 29(2):72-79
8. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9(14):5295-5298
9. Jain S, Chang TT, Hamilton JP, Lin SY, Lin YJ, Evans AA, Selaru FM, Lin PW, Chen SH, Block TM (2011) Methylation of the CpG Sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS ONE 6(11):e26799
10. Jain S, Chen S, Chang KC, Lin YJ, Hu CT, Boldbaatar B, Hamilton JP, Lin SY, Chang TT, Chen SH (2012) Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS ONE 7(4):e35789
11. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, Cho JW, Park YM, Jung G (2008) Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135(6):2128-2140
12. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163(4):1371
13. Wang X, Meng X, Sun X, Liu M, Gao S, Zhao J, Pei F, Yu H (2009) Wnt/β-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle 8(10):1567-1570
14. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M (2009) Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9(1):125
15. Tanaka S, Shiraha H, Nakanishi Y, Nishina SI, Matsubara M, Horiguchi S, Takaoka N, Iwamuro M, Kataoka J, Kuwaki K (2012) Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer 131:2537-2546
16. Van Laer L, Huizing EH, Verstreken M, Van Zuijlen D, Wauters JG, Bossuyt PJ, Van de Heyning P, McGuirt WT, Smith RJH, Willems PJ (1998) Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet 20(2):194-197
17. Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, Nishikawa N, Watanabe Y, Sasaki Y, Abe T (2006) Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci 98(1):88-95
18. Kim M, Chang X, Yamashita K, Nagpal J, Baek J, Wu G, Trink B, Ratovitski E, Mori M, Sidransky D (2008) Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene 27(25):3624-3634
19. Kim MS, Lebron C, Nagpal JK, Chae YK, Chang X, Huang Y, Chuang T, Yamashita K, Trink B, Ratovitski EA (2008) Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophy Res Commu 370(1):38-43
20. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T (2010) Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Tr 122(3):699-710
21. De Beeck KO, Van Camp G, Thys S, Cools N, Callebaut I, Vrijens K, Van Nassauw L, Van Tendeloo VFI, Timmermans JP, Van Laer L (2011) The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. Eur J Human Genet 19(9):965-973
22. Searle J, Harmon B, Bishop C, Kerr J (2008) The significance of cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol 2(1):77-96
23. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5(3):231-237
24. Kaufmann T, Strasser A, Jost P (2011) Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19(1):42-50
25. Higaki K, Yano H, Kojiro M (1996) Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 149(2):429
26. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37
27. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59(20):5356-5364
28. Ryan AE, Shanahan F, O'Connell J, Houston AM (2006) Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 5(3):246-249
29. Kykalos S, Mathaiou S, Karayiannakis AJ, Patsouras D, Lambropoulou M, Simopoulos C (2012) Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer 43(2):224-228
30. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR (2003) A unified model for apical caspase activation. Mol Cell 11(2):529-541
31. Stennicke HR, Jürgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D (1998) Pro-caspase-3 is a major physiologic target of caspase-8. J Biological Chem 273(42):27084-27090
32. Fulda S (2009) Caspase-8 in cancer biology and therapy. Cancer Lett 281(2):128-133
33. Lavrik I, Krammer P (2011) Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 19(1):36-41
34. Bucher N, Britten C (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Bri J cancer 98(3):523-528
35. Zhang L, Ruan J, Yan L, Li W, Wu Y, Tao L, Zhang F, Zheng S, Wang A, Lu Y (2012) Xanthatin induces cell cycle arrest at G2/M checkpoint and apoptosis via disrupting NF-κB pathway in A549 non-small-cell lung cancer cells. Molecules 17(4):3736-3750